{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:30:13Z","timestamp":1768311013937,"version":"3.49.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1212\/con.0000000000000353","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T12:49:40Z","timestamp":1470746980000},"page":"1086-1103","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Neuropsychiatric Issues in Parkinson Disease"],"prefix":"10.1212","volume":"22","author":[{"given":"Jennifer G.","family":"Goldman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"4","key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.parkreldis.2014.01.001","article-title":"Hypomania and mania related to dopamine replacement therapy in Parkinson\u2019s disease","volume":"20","author":"Maier F","year":"2014","unstructured":"Maier F Merkl J Ellereit AL Hypomania and mania related to dopamine replacement therapy in Parkinson\u2019s disease. Parkinsonism Relat Disord 2014;20(4):421\u2013427. doi:10.1016\/j.parkreldis.2014.01.001.","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/B978-0-444-53497-2.00012-7","article-title":"Psychiatric considerations in deep brain stimulation for Parkinson\u2019s disease","volume":"116","author":"Voon V","year":"2013","unstructured":"Voon V Howell NA Krack P. Psychiatric considerations in deep brain stimulation for Parkinson\u2019s disease. Handb Clin Neurol 2013;116:147\u2013154. doi:10.1016\/B978-0-444-53497-2.00012-7.","journal-title":"Handb Clin Neurol"},{"issue":"2","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mds.21803","article-title":"A systematic review of prevalence studies of depression in Parkinson\u2019s disease","volume":"23","author":"Reijnders JS","year":"2008","unstructured":"Reijnders JS Ehrt U Weber WE A systematic review of prevalence studies of depression in Parkinson\u2019s disease. Mov Disord 2008;23(2):183\u2013189; quiz 313. doi:10.1002\/mds.21803.","journal-title":"Mov Disord"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders, fifth edition","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition. Washington, DC: American Psychiatric Publishing, 2013."},{"key":"e_1_3_1_6_2","volume-title":"Diagnostic and statistical manual of mental disorders, fourth edition","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition. Washington, DC: American Psychiatric Publishing, 2000."},{"issue":"2","key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/mds.20723","article-title":"Provisional diagnostic criteria for depression in Parkinson\u2019s disease: report of an NINDS\/NIMH Work Group","volume":"21","author":"Marsh L","year":"2006","unstructured":"Marsh L McDonald WM Cummings J Ravina B; NINDS\/NIMH Work Group on Depression and Parkinson\u2019s Disease. Provisional diagnostic criteria for depression in Parkinson\u2019s disease: report of an NINDS\/NIMH Work Group. Mov Disord 2006;21(2):148\u2013158. doi:10.1002\/mds.20723.","journal-title":"Mov Disord"},{"issue":"11","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/mds.22130","article-title":"Suicidal and death ideation in Parkinson\u2019s disease","volume":"23","author":"Nazem S","year":"2008","unstructured":"Nazem S Siderowf AD Duda JE Suicidal and death ideation in Parkinson\u2019s disease. Mov Disord 2008;23(11):1573\u20131579. doi:10.1002\/mds.22130.","journal-title":"Mov Disord"},{"issue":"10","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.parkreldis.2012.06.007","article-title":"Anxiety and motor fluctuations in Parkinson\u2019s disease: a cross-sectional observational study","volume":"18","author":"Leentjens AF","year":"2012","unstructured":"Leentjens AF Dujardin K Marsh L Anxiety and motor fluctuations in Parkinson\u2019s disease: a cross-sectional observational study. Parkinsonism Relat Disord 2012;18(10):1084\u20131088. doi:10.1016\/j.parkreldis.2012.06.007.","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/mds.23092","article-title":"Depression and the subsequent risk of Parkinson\u2019s disease in the NIH-AARP Diet and Health Study","volume":"25","author":"Fang F","year":"2010","unstructured":"Fang F Xu Q Park Y Depression and the subsequent risk of Parkinson\u2019s disease in the NIH-AARP Diet and Health Study. Mov Disord 2010;25(9):1157\u20131162. doi:10.1002\/mds.23092.","journal-title":"Mov Disord"},{"issue":"12","key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.0000000000000801","article-title":"Course of psychiatric symptoms and global cognition in early Parkinson disease","volume":"83","author":"de la Riva P","year":"2014","unstructured":"de la Riva P Smith K Xie SX Weintraub D. Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology 2014;83(12):1096\u20131103. doi:10.1212\/WNL.0000000000000801.","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jad.2011.01.021","article-title":"Factors associated with depression in Parkinson\u2019s disease","volume":"132","author":"Dissanayaka NN","year":"2011","unstructured":"Dissanayaka NN Sellbach A Silburn PA Factors associated with depression in Parkinson\u2019s disease. J Affect Disord 2011;132(1\u20132):82\u201388. doi:10.1016\/j.jad.2011.01.021.","journal-title":"J Affect Disord"},{"issue":"8","key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.21333","article-title":"Depression rating scales in Parkinson\u2019s disease: critique and recommendations","volume":"22","author":"Schrag A","year":"2007","unstructured":"Schrag A Barone P Brown RG Depression rating scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord 2007;22(8):1077\u20131092. doi:10.1002\/mds.21333.","journal-title":"Mov Disord"},{"issue":"3","key":"e_1_3_1_14_2","first-page":"S42","article-title":"The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson\u2019s disease","volume":"26","author":"Seppi K","year":"2011","unstructured":"Seppi K Weintraub D Coelho M The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson\u2019s disease. Mov Disord 2011;26(suppl 3):S42\u2013S80. doi:10.1002\/mds.23884.","journal-title":"Mov Disord"},{"issue":"3","key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.nbd.2011.12.041","article-title":"Psychosis, apathy, depression and anxiety in Parkinson\u2019s disease","volume":"46","author":"Gallagher DA","year":"2012","unstructured":"Gallagher DA Schrag A. Psychosis, apathy, depression and anxiety in Parkinson\u2019s disease. Neurobiol Dis 2012;46(3):581\u2013589. doi:10.1016\/j.nbd.2011.12.041.","journal-title":"Neurobiol Dis"},{"issue":"16","key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease","volume":"78","author":"Richard IH","year":"2012","unstructured":"Richard IH McDermott MP Kurlan R A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78(16):1229\u20131236. doi:10.1212\/WNL.0b013e3182516244.","journal-title":"Neurology"},{"issue":"10","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza M","year":"2009","unstructured":"Menza M Dobkin RD Marin H A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72(10):886\u2013892. doi:10.1212\/01.wnl.0000336340.89821.b3.","journal-title":"Neurology"},{"issue":"6","key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Devos D","year":"2008","unstructured":"Devos D Dujardin K Poirot I Comparison of desipramine and citalopram treatments for depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008;23(6):850\u2013857. doi:10.1002\/mds.21966.","journal-title":"Mov Disord"},{"issue":"10","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1176\/appi.ajp.2011.10111669","article-title":"Cognitive-behavioral therapy for depression in Parkinson\u2019s disease: a randomized, controlled trial","volume":"168","author":"Dobkin RD","year":"2011","unstructured":"Dobkin RD Menza M Allen LA Cognitive-behavioral therapy for depression in Parkinson\u2019s disease: a randomized, controlled trial. Am J Psychiatry 2011;168(10):1066\u20131074. doi:10.1176\/appi.ajp.2011.10111669.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/mds.25937","article-title":"The clinical spectrum of anxiety in Parkinson\u2019s disease","volume":"29","author":"Dissanayaka NN","year":"2014","unstructured":"Dissanayaka NN White E O\u2019Sullivan JD The clinical spectrum of anxiety in Parkinson\u2019s disease. Mov Disord 2014;29(8):967\u2013975. doi:10.1002\/mds.25937.","journal-title":"Mov Disord"},{"issue":"12","key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.jagp.2013.09.006","article-title":"Anxiety has specific syndromal profiles in Parkinson disease: a data-driven approach","volume":"22","author":"Starkstein SE","year":"2014","unstructured":"Starkstein SE Dragovic M Dujardin K Anxiety has specific syndromal profiles in Parkinson disease: a data-driven approach. Am J Geriatr Psychiatry 2014;22(12):1410\u20131417. doi:10.1016\/j.jagp.2013.09.006.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.parkreldis.2014.03.020","article-title":"Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson\u2019s disease","volume":"20","author":"Sagna A","year":"2014","unstructured":"Sagna A Gallo JJ Pontone GM. Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson\u2019s disease. Parkinsonism Relat Disord 2014;20(7):708\u2013715. doi:10.1016\/j.parkreldis.2014.03.020.","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/mds.20980","article-title":"What is the evidence for a premorbid parkinsonian personality: a systematic review","volume":"21","author":"Ishihara L","year":"2006","unstructured":"Ishihara L Brayne C. What is the evidence for a premorbid parkinsonian personality: a systematic review. Mov Disord 2006;21(8):1066\u20131072. doi:10.1002\/mds.20980.","journal-title":"Mov Disord"},{"issue":"2","key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/mds.25664","article-title":"Health-related quality of life in early Parkinson\u2019s disease: the impact of nonmotor symptoms","volume":"29","author":"Duncan GW","year":"2014","unstructured":"Duncan GW Khoo TK Yarnall AJ Health-related quality of life in early Parkinson\u2019s disease: the impact of nonmotor symptoms. Mov Disord 2014;29(2):195\u2013202. doi:10.1002\/mds.25664.","journal-title":"Mov Disord"},{"issue":"11","key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.22643","article-title":"The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease","volume":"24","author":"Barone P","year":"2009","unstructured":"Barone P Antonini A Colosimo C The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson\u2019s disease. Mov Disord 2009;24(11):1641\u20131649. doi:10.1002\/mds.22643.","journal-title":"Mov Disord"},{"issue":"14","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/mds.22233","article-title":"Anxiety rating scales in Parkinson\u2019s disease: critique and recommendations","volume":"23","author":"Leentjens AF","year":"2008","unstructured":"Leentjens AF Dujardin K Marsh L Anxiety rating scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord 2008;23(14):2015\u20132025. doi:10.1002\/mds.22233.","journal-title":"Mov Disord"},{"issue":"6","key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jagp.2012.10.023","article-title":"Pharmacologic treatment of anxiety disorders in Parkinson disease","volume":"21","author":"Pontone GM","year":"2013","unstructured":"Pontone GM Williams JR Anderson KE Pharmacologic treatment of anxiety disorders in Parkinson disease. Am J Geriatr Psychiatry 2013;21(6):520\u2013528. doi:10.1016\/j.jagp.2012.10.023.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/mds.23823","article-title":"MDS Task Force on mild cognitive impairment in Parkinson\u2019s disease: critical review of PD-MCI","volume":"26","author":"Litvan I","year":"2011","unstructured":"Litvan I Aarsland D Adler CH MDS Task Force on mild cognitive impairment in Parkinson\u2019s disease: critical review of PD-MCI. Mov Disord 2011;26(10):1814\u20131824. doi:10.1002\/mds.23823.","journal-title":"Mov Disord"},{"issue":"3","key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1750-3639.2009.00369.x","article-title":"The epidemiology of dementia associated with Parkinson\u2019s disease","volume":"20","author":"Aarsland D","year":"2010","unstructured":"Aarsland D Kurz MW. The epidemiology of dementia associated with Parkinson\u2019s disease. Brain Pathol 2010;20(3):633\u2013639. doi:10.1111\/j.1750-3639.2009.00369.x.","journal-title":"Brain Pathol"},{"issue":"3","key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.24893","article-title":"Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines","volume":"27","author":"Litvan I","year":"2012","unstructured":"Litvan I Goldman JG Tr\u00f6ster AI Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27(3):349\u2013356. doi:10.1002\/mds.24893.","journal-title":"Mov Disord"},{"issue":"12","key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","article-title":"Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease","volume":"22","author":"Emre M","year":"2007","unstructured":"Emre M Aarsland D Brown R Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord 2007;22(12):1689\u20131707; quiz 837. doi:10.1002\/mds.21507.","journal-title":"Mov Disord"},{"issue":"7","key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/brain\/awm111","article-title":"Evolution of cognitive dysfunction in an incident Parkinson\u2019s disease cohort","volume":"130","author":"Williams-Gray CH","year":"2007","unstructured":"Williams-Gray CH Foltynie T Brayne CE Evolution of cognitive dysfunction in an incident Parkinson\u2019s disease cohort. Brain 2007;130(pt 7):1787\u20131798. doi:10.1093\/brain\/awm111.","journal-title":"Brain"},{"issue":"13","key":"e_1_3_1_33_2","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1212\/01.wnl.0000338632.00552.cb","article-title":"Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study","volume":"72","author":"Aarsland D","year":"2009","unstructured":"Aarsland D Br\u00f8nnick K Larsen JP Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009;72(13):1121\u20131126. doi:10.1212\/01.wnl.0000338632.00552.cb.","journal-title":"Neurology"},{"issue":"4","key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1212\/WNL.0000000000000066","article-title":"Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study","volume":"82","author":"Yarnall AJ","year":"2014","unstructured":"Yarnall AJ Breen DP Duncan GW Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 2014;82(4):308\u2013316. doi:10.1212\/WNL.0000000000000066.","journal-title":"Neurology"},{"issue":"7","key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.26170","article-title":"Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease","volume":"30","author":"Weintraub D","year":"2015","unstructured":"Weintraub D Simuni T Caspell-Garcia C Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease. Mov Disord 2015;30(7):919\u2013927. doi:10.1002\/mds.26170.","journal-title":"Mov Disord"},{"issue":"5","key":"e_1_3_1_36_2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/mds.25857","article-title":"The neurobiological basis of cognitive impairment in Parkinson\u2019s disease","volume":"29","author":"Halliday GM","year":"2014","unstructured":"Halliday GM Leverenz JB Schneider JS Adler CH. The neurobiological basis of cognitive impairment in Parkinson\u2019s disease. Mov Disord 2014;29(5):634\u2013650. doi:10.1002\/mds.25857.","journal-title":"Mov Disord"},{"issue":"11","key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/mds.26352","article-title":"Advances in the treatment of cognitive impairment in Parkinson\u2019s disease","volume":"30","author":"Goldman JG","year":"2015","unstructured":"Goldman JG Weintraub D. Advances in the treatment of cognitive impairment in Parkinson\u2019s disease. Mov Disord 2015;30(11):1471\u20131489. doi:10.1002\/mds.26352.","journal-title":"Mov Disord"},{"issue":"24","key":"e_1_3_1_38_2","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson\u2019s disease","volume":"351","author":"Emre M","year":"2004","unstructured":"Emre M Aarsland D Albanese A Rivastigmine for dementia associated with Parkinson\u2019s disease. N Engl J Med 2004;351(24):2509\u20132518. doi:10.1056\/NEJMoa041470.","journal-title":"N Engl J Med"},{"issue":"10","key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/mds.25098","article-title":"Donepezil in Parkinson\u2019s disease dementia: a randomized, double-blind efficacy and safety study","volume":"27","author":"Dubois B","year":"2012","unstructured":"Dubois B Tolosa E Katzenschlager R Donepezil in Parkinson\u2019s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord 2012;27(10):1230\u20131238. doi:10.1002\/mds.25098.","journal-title":"Mov Disord"},{"issue":"1","key":"e_1_3_1_40_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/WNF.0000000000000010","article-title":"Long-term safety of rivastigmine in Parkinson disease dementia: an open-label, randomized study","volume":"37","author":"Emre M","year":"2014","unstructured":"Emre M Poewe W De Deyn PP Long-term safety of rivastigmine in Parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol 2014;37(1):9\u201316. doi:10.1097\/WNF.0000000000000010.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"e_1_3_1_41_2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","article-title":"Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Emre M","year":"2010","unstructured":"Emre M Tsolaki M Bonuccelli U Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(10):969\u2013977. doi:10.1016\/S1474-4422(10)70194-0.","journal-title":"Lancet Neurol"},{"issue":"7","key":"e_1_3_1_42_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1474-4422(09)70146-2","article-title":"Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial","volume":"8","author":"Aarsland D","year":"2009","unstructured":"Aarsland D Ballard C Walker Z Memantine in patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8(7):613\u2013618. doi:10.1016\/S1474-4422(09)70146-2.","journal-title":"Lancet Neurol"},{"issue":"8","key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/mds.25377","article-title":"Nonpharmacological enhancement of cognitive function in Parkinson\u2019s disease: a systematic review","volume":"28","author":"Hindle JV","year":"2013","unstructured":"Hindle JV Petrelli A Clare L Kalbe E. Nonpharmacological enhancement of cognitive function in Parkinson\u2019s disease: a systematic review. Mov Disord 2013;28(8):1034\u20131349. doi:10.1002\/mds.25377.","journal-title":"Mov Disord"},{"issue":"5","key":"e_1_3_1_44_2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","article-title":"Apathy in Parkinson\u2019s disease: clinical features, neural substrates, diagnosis, and treatment","volume":"14","author":"Pagonabarraga J","year":"2015","unstructured":"Pagonabarraga J Kulisevsky J Strafella AP Krack P. Apathy in Parkinson\u2019s disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015;14(5):518\u2013531. doi:10.1016\/S1474-4422(15)00019-8.","journal-title":"Lancet Neurol"},{"issue":"6","key":"e_1_3_1_45_2","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1017\/S1355617711001068","article-title":"Apathy and depression: separate factors in Parkinson\u2019s disease","volume":"17","author":"Kirsch-Darrow L","year":"2011","unstructured":"Kirsch-Darrow L Marsiske M Okun MS Apathy and depression: separate factors in Parkinson\u2019s disease. J Int Neuropsychol Soc 2011;17(6):1058\u20131066. doi:10.1017\/S1355617711001068.","journal-title":"J Int Neuropsychol Soc"},{"issue":"16","key":"e_1_3_1_46_2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/mds.22843","article-title":"Apathy may herald cognitive decline and dementia in Parkinson\u2019s disease","volume":"24","author":"Dujardin K","year":"2009","unstructured":"Dujardin K Sockeel P Delliaux M Apathy may herald cognitive decline and dementia in Parkinson\u2019s disease. Mov Disord 2009;24(16):2391\u20132397. doi:10.1002\/mds.22843.","journal-title":"Mov Disord"},{"issue":"14","key":"e_1_3_1_47_2","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/mds.26058","article-title":"Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms","volume":"29","author":"Dujardin K","year":"2014","unstructured":"Dujardin K Langlois C Plomhause L Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms. Mov Disord 2014;29(14):1796\u20131801. doi:10.1002\/mds.26058.","journal-title":"Mov Disord"},{"issue":"1","key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/jnnp-2012-303419","article-title":"Non-motor symptoms in early Parkinson\u2019s disease: a 2-year follow-up study on previously untreated patients","volume":"84","author":"Erro R","year":"2013","unstructured":"Erro R Picillo M Vitale C Non-motor symptoms in early Parkinson\u2019s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 2013;84(1):14\u201317. doi:10.1136\/jnnp-2012-303419.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"e_1_3_1_49_2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/brain\/awq032","article-title":"Non-motor dopamine withdrawal syndrome after surgery for Parkinson\u2019s disease: predictors and underlying mesolimbic denervation","volume":"133","author":"Thobois S","year":"2010","unstructured":"Thobois S Ardouin C Lhomm\u00e9e E Non-motor dopamine withdrawal syndrome after surgery for Parkinson\u2019s disease: predictors and underlying mesolimbic denervation. Brain 2010;133(pt 4):1111\u20131127. doi:10.1093\/brain\/awq032.","journal-title":"Brain"},{"issue":"14","key":"e_1_3_1_50_2","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/mds.22229","article-title":"Apathy and anhedonia rating scales in Parkinson\u2019s disease: critique and recommendations","volume":"23","author":"Leentjens AF","year":"2008","unstructured":"Leentjens AF Dujardin K Marsh L Apathy and anhedonia rating scales in Parkinson\u2019s disease: critique and recommendations. Mov Disord 2008;23(14):2004\u20132014. doi:10.1002\/mds.22229.","journal-title":"Mov Disord"},{"issue":"6","key":"e_1_3_1_51_2","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2013-306439","article-title":"Rivastigmine in apathetic but dementia and depression-free patients with Parkinson\u2019s disease: a double-blind, placebo-controlled, randomised clinical trial","volume":"85","author":"Devos D","year":"2014","unstructured":"Devos D Moreau C Malt\u00eate D Rivastigmine in apathetic but dementia and depression-free patients with Parkinson\u2019s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014;85(6):668\u2013674. doi:10.1136\/jnnp-2013-306439.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"e_1_3_1_52_2","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/brain\/awt067","article-title":"Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil","volume":"136","author":"Thobois S","year":"2013","unstructured":"Thobois S Lhomm\u00e9e E Klinger H Parkinsonian apathy responds to dopaminergic stimulation of D2\/D3 receptors with piribedil. Brain 2013;136(pt 5):1568\u20131577. doi:10.1093\/brain\/awt067.","journal-title":"Brain"},{"issue":"2","key":"e_1_3_1_53_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.26016","article-title":"Clinical spectrum of impulse control disorders in Parkinson\u2019s disease","volume":"30","author":"Weintraub D","year":"2015","unstructured":"Weintraub D David AS Evans AH Clinical spectrum of impulse control disorders in Parkinson\u2019s disease. Mov Disord 2015;30(2):121\u2013127. doi:10.1002\/mds.26016.","journal-title":"Mov Disord"},{"issue":"5","key":"e_1_3_1_54_2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub D","year":"2010","unstructured":"Weintraub D Koester J Potenza MN Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67(5):589\u2013595. doi:10.1001\/archneurol.2010.65.","journal-title":"Arch Neurol"},{"issue":"3","key":"e_1_3_1_55_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/mds.23501","article-title":"Impulsivity and compulsivity in drug-na\u00efve patients with Parkinson\u2019s disease","volume":"26","author":"Antonini A","year":"2011","unstructured":"Antonini A Siri C Santangelo G Impulsivity and compulsivity in drug-na\u00efve patients with Parkinson\u2019s disease. Mov Disord 2011;26(3):464\u2013468. doi:10.1002\/mds.23501.","journal-title":"Mov Disord"},{"issue":"2","key":"e_1_3_1_56_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mds.26068","article-title":"Linking neuroscience with modern concepts of impulse control disorders in Parkinson\u2019s disease","volume":"30","author":"Napier TC","year":"2015","unstructured":"Napier TC Corvol JC Grace AA Linking neuroscience with modern concepts of impulse control disorders in Parkinson\u2019s disease. Mov Disord 2015;30(2):141\u2013149. doi:10.1002\/mds.26068.","journal-title":"Mov Disord"},{"issue":"2","key":"e_1_3_1_57_2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mds.24023","article-title":"Questionnaire for Impulsive-Compulsive Disorders in Parkinson\u2019s Disease-Rating Scale","volume":"27","author":"Weintraub D","year":"2012","unstructured":"Weintraub D Mamikonyan E Papay K Questionnaire for Impulsive-Compulsive Disorders in Parkinson\u2019s Disease-Rating Scale. Mov Disord 2012;27(2):242\u2013247. doi:10.1002\/mds.24023.","journal-title":"Mov Disord"},{"issue":"1","key":"e_1_3_1_58_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak CA","year":"2010","unstructured":"Rabinak CA Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67(1):58\u201363. doi:10.1001\/archneurol.2009.294.","journal-title":"Arch Neurol"},{"issue":"1","key":"e_1_3_1_59_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","article-title":"Epidemiology of psychosis in Parkinson\u2019s disease","volume":"289","author":"F\u00e9nelon G","year":"2010","unstructured":"F\u00e9nelon G Alves G. Epidemiology of psychosis in Parkinson\u2019s disease. J Neurol Sci 2010;289(1\u20132):12\u201317. doi:10.1016\/j.jns.2009.08.014.","journal-title":"J Neurol Sci"},{"issue":"8","key":"e_1_3_1_60_2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/mds.21382","article-title":"Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group","volume":"22","author":"Ravina B","year":"2007","unstructured":"Ravina B Marder K Fernandez HH Diagnostic criteria for psychosis in Parkinson\u2019s disease: report of an NINDS, NIMH work group. Mov Disord 2007;22(8):1061\u20131068. doi:10.1002\/mds.21382.","journal-title":"Mov Disord"},{"issue":"6","key":"e_1_3_1_61_2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/mds.22839","article-title":"The changing face of Parkinson\u2019s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria","volume":"25","author":"F\u00e9nelon G","year":"2010","unstructured":"F\u00e9nelon G Soulas T Zenasni F The changing face of Parkinson\u2019s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord 2010;25(6):763\u2013766. doi:10.1002\/mds.22839.","journal-title":"Mov Disord"},{"issue":"12","key":"e_1_3_1_62_2","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/mds.23835","article-title":"Visual plus nonvisual hallucinations in Parkinson\u2019s disease: development and evolution over 10 years","volume":"26","author":"Goetz CG","year":"2011","unstructured":"Goetz CG Stebbins GT Ouyang B. Visual plus nonvisual hallucinations in Parkinson\u2019s disease: development and evolution over 10 years. Mov Disord 2011;26(12):2196\u20132200. doi:10.1002\/mds.23835.","journal-title":"Mov Disord"},{"issue":"4","key":"e_1_3_1_63_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mds.21875","article-title":"Scales to assess psychosis in Parkinson\u2019s disease: critique and recommendations","volume":"23","author":"Fernandez HH","year":"2008","unstructured":"Fernandez HH Aarsland D F\u00e9nelon G Scales to assess psychosis in Parkinson\u2019s disease: critique and recommendations. Mov Disord 2008;23(4):484\u2013500. doi:10.1002\/mds.21875.","journal-title":"Mov Disord"},{"issue":"3","key":"e_1_3_1_64_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.parkreldis.2012.10.022","article-title":"Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson\u2019s disease psychosis","volume":"19","author":"Voss T","year":"2013","unstructured":"Voss T Bahr D Cummings J Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson\u2019s disease psychosis. Parkinsonism Relat Disord 2013;19(3):295\u2013299. doi:10.1016\/j.parkreldis.2012.10.022.","journal-title":"Parkinsonism Relat Disord"},{"issue":"9916","key":"e_1_3_1_65_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings J","year":"2014","unstructured":"Cummings J Isaacson S Mills R Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014;383(9916):533\u2013540. doi:10.1016\/S0140-6736(13)62106-6.","journal-title":"Lancet"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00132979-201608000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:08:07Z","timestamp":1752156487000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1212\/CON.0000000000000353"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000353","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}